Immunotherapy-based regimens as evolving strategies for management of metastatic urothelial carcinoma
13 Feb 2020
byDr Margaret Shi
Immunotherapy-chemotherapy combinations, immunotherapy doublets, and combinations of immunotherapy with novel targeted agents are emerging as strategies for management of metastatic urothelial carcinoma (mUC) in view of the limitations with chemotherapy and single-agent immunotherapy, said an expert at the Uro-Oncology Asia 2020 conference.